Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
FACTOR IX, HUMAN
Octapharma Limited
1000IU Units/ml
Pdr+Solv for Soln for Inj
2007-03-09
PART II SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Nanotiv 1000 IU, powder and solvent for solution for injection and infusion. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Nanotiv is presented as a powder and solvent for solution for injection and infusion containing nominally 1000 IU human coagulation factor IX per vial. The product contains approximately 100 IU/ml human coagulation factor IX when reconstituted with 10 ml Water for Injections. The potency (IU) is determined using the European Pharmacopoeia one stage clotting test. The specific activity of Nanotiv is approximately 190 IU/mg protein. For excipients, see 6.1. 3 PHARMACEUTICAL FORM Powder and solvent for solution for injection and infusion. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency). Nanotiv may be used in the management of acquired factor IX deficiency. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Treatment should be initiated under the supervision of a physician experienced in the treatment of haemophilia. POSOLOGY The dosage and duration of substitution therapy depend on the severity of the factor IX deficiency, on the location and extent of the bleeding and the patient’s clinical condition. The number of units of factor IX administered is expressed in International Units (IU), which are related to the current WHO standard for factor IX products. Factor IX activity in plasma is expressed either as a percentage (relative to normal human plasma) or in International Units (relative to an international standard for factor IX in plasma). One International Unit of factor IX activity is equivalent to that quantity of factor IX in one ml of normal human plasma. The calculation of Read the complete document